JP2012512885A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512885A5
JP2012512885A5 JP2011542413A JP2011542413A JP2012512885A5 JP 2012512885 A5 JP2012512885 A5 JP 2012512885A5 JP 2011542413 A JP2011542413 A JP 2011542413A JP 2011542413 A JP2011542413 A JP 2011542413A JP 2012512885 A5 JP2012512885 A5 JP 2012512885A5
Authority
JP
Japan
Prior art keywords
ethyl
benzyloxyimino
azetidine
cyclohexyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011542413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512885A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/068352 external-priority patent/WO2010080455A1/en
Publication of JP2012512885A publication Critical patent/JP2012512885A/ja
Publication of JP2012512885A5 publication Critical patent/JP2012512885A5/ja
Pending legal-status Critical Current

Links

JP2011542413A 2008-12-18 2009-12-17 新規な塩 Pending JP2012512885A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20305108P 2008-12-18 2008-12-18
US61/203,051 2008-12-18
PCT/US2009/068352 WO2010080455A1 (en) 2008-12-18 2009-12-17 New salts

Publications (2)

Publication Number Publication Date
JP2012512885A JP2012512885A (ja) 2012-06-07
JP2012512885A5 true JP2012512885A5 (https=) 2012-11-22

Family

ID=42316715

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542413A Pending JP2012512885A (ja) 2008-12-18 2009-12-17 新規な塩

Country Status (12)

Country Link
US (2) US8486930B2 (https=)
EP (1) EP2379499B1 (https=)
JP (1) JP2012512885A (https=)
KR (1) KR20110101159A (https=)
CN (2) CN103204794A (https=)
AU (1) AU2009335887A1 (https=)
BR (1) BRPI0922466A2 (https=)
CA (1) CA2747558A1 (https=)
ES (1) ES2478842T3 (https=)
MX (1) MX2011006622A (https=)
RU (1) RU2011129229A (https=)
WO (1) WO2010080455A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103003253A (zh) * 2010-08-05 2013-03-27 贝林格尔.英格海姆国际有限公司 2-{2-[[(4-甲氧基-2,6-二甲基苯基)磺酰基]-(甲基)氨基]乙氧基}-n-甲基-n-[3-(4-甲基哌嗪-1-基)环己基]乙酰胺的酸加成盐及其作为缓激肽b1受体拮抗剂的用途
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
US20190047951A1 (en) 2016-01-04 2019-02-14 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11958805B2 (en) * 2017-03-09 2024-04-16 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2019064184A1 (en) 2017-09-27 2019-04-04 Dr. Reddy's Laboratories Limited PROCESS FOR THE PREPARATION OF SIPONIMOD, ITS SALTS AND ASSOCIATED SOLID STATE FORMS
CA3073910A1 (en) 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
EP3687531A1 (en) 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
WO2019144094A1 (en) * 2018-01-22 2019-07-25 Teva Pharmaceuticals International Gmbh Crystalline siponimod fumaric acid and polymorphs thereof
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
KR20210134065A (ko) * 2019-03-28 2021-11-08 주식회사 퍼스트바이오테라퓨틱스 벤조티아졸 화합물의 약제학적 염, 다형체 및 이들의 제조 방법
WO2020234423A1 (en) 2019-05-21 2020-11-26 Synthon B.V. Siponimod maleic acid and fumaric acid salt
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Cxcr7アンタゴニストのs1p1受容体調節剤との合剤
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
WO2022064007A1 (en) 2020-09-25 2022-03-31 Synthon B.V. Siponimod salts and cocrystals
CN112402610A (zh) * 2020-11-20 2021-02-26 睿阜隆(杭州)生物医药有限公司 1-磷酸鞘氨醇受体调节剂在制备治疗糖尿病的药物中的新用途
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
CA2258548C (en) 1996-06-24 2005-07-26 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU735648B2 (en) 1996-07-12 2001-07-12 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
EP0954315A2 (en) 1996-09-13 1999-11-10 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
CN1660840A (zh) 1999-03-30 2005-08-31 诺瓦提斯公司 治疗炎性疾病的酞嗪衍生物
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
MXPA05012459A (es) * 2003-05-19 2006-02-22 Irm Llc Compuestos y composiciones inmunosupresoras.
KR20070085465A (ko) 2004-11-29 2007-08-27 노파르티스 아게 S1p 수용체 효능제의 투여 용법
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2012512885A5 (https=)
JP2014515013A5 (https=)
JP2015145426A5 (https=)
JP2012507535A5 (https=)
JP2010513478A5 (https=)
JP2018024682A5 (https=)
JO2894B1 (en) Salt and new amorphous images
JP2010047578A5 (https=)
JP2017527578A5 (https=)
JP2012533546A5 (https=)
JP2013507408A5 (https=)
JP2012530705A5 (https=)
JP2014525470A5 (https=)
JP2013525444A5 (https=)
JP2013530958A5 (https=)
JP2010505906A5 (https=)
JP2011518833A5 (https=)
JP2019510768A5 (https=)
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2012180360A5 (https=)
RU2019112080A (ru) Соли производного индазола и их кристаллы
RU2016141650A (ru) Амидные соединения
WO2009126861A3 (en) Triazolopyridine compounds useful as dgat1 inhibitors
JP2009517353A5 (https=)
JP2014067585A5 (https=)